Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 18/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13913670 | 0.81 | ADORA1 (1.00) | ADORA1ADORA2BMEN1KMT2A | |
| SCHEMBL13036497 | 0.81 | ADORA1 (0.68) | ADORA1ADORA2B | |
| SCHEMBL3544024 | 0.80 | L3MBTL1 (0.45) | ADORA1MEN1KMT2A | |
| SCHEMBL13036490 | 0.80 | ADORA1 (0.67) | ADORA1ADORA2B | |
| SCHEMBL13036501 | 0.77 | ADORA1 (0.67) | ADORA1 | |
| SCHEMBL13036505 | 0.75 | ADORA1 (0.64) | ADORA1 | |
| SCHEMBL13036494 | 0.74 | ADORA1 (0.59) | ADORA1 | |
| SCHEMBL3545556 | 0.73 | TDP1 (0.49) | ADORA1MEN1KMT2A | |
| SCHEMBL13074253 | 0.72 | ADORA1 (0.66) | ADORA1ADORA2B | |
| SCHEMBL13913771 | 0.72 | ADORA1 (1.00) | ADORA1ADORA2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825255-B2 | Adenosine receptor selective modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-02 | — | — | US | disclosed |
| US-7825255-B2 | Adenosine receptor selective modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-02 | — | — | US | disclosed |
| US-7825255-B2 | Adenosine receptor selective modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-02 | — | — | US | disclosed |
| EP-1368319-B1 | SUBSTITUTED 2-THIO-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS | BAYER HEALTHCARE AG (DE) | 2006-12-06 | — | — | EP | disclosed |
| US-20060154969-A1 | Adenosine receptor selective modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154969-A1 | Adenosine receptor selective modulators | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2B 4/4885MEN1 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.